↓ Skip to main content

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

Overview of attention for article published in Frontiers in Pharmacology, July 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
4 X users

Readers on

mendeley
18 Mendeley